Advertisement
Screener

WAVE LIFE SCIENCES LTD. (WVE) Overview

WAVE LIFE SCIENCES LTD. (WVE) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.34; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.13; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.32; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.31; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$3.20$4.72$6.97$10.28$15.17$22.382025-11-062026-11-06$1.17$2.11$3.81$6.87$12.40$22.382021-11-082026-11-06$1.17$2.55$5.57$12.16$26.55$57.962016-11-072026-11-06$1.17$2.55$5.57$12.16$26.55$57.962015-11-112026-11-06$1.17$2.55$5.57$12.16$26.55$57.962015-11-112026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$3.37
Previous close
$3.64
Change
-$0.27
Change (%)
-7.42%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

WVE
-78.59%
S&P 500
(m)

1 year

WVE
-48.95%
S&P 500
(m)

3 years

WVE
-36.70%
S&P 500
(m)

5 years

WVE
-25.56%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.34

-0.42-0.30-0.19-0.070.0531 Mar 2025: estimate (m); actual -0.2931 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.3130 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.3230 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1331 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.3430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.34(m)(m)
1 Jan 202631 Mar 2026(m)-0.13(m)(m)
1 Jul 202530 Sept 2025(m)-0.32(m)(m)
1 Apr 202530 Jun 2025(m)-0.31(m)(m)
1 Jan 202531 Mar 2025(m)-0.29(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.21

-2.44-1.92-1.40-0.88-0.3631 Dec 2021: estimate (m); actual -2.3631 Dec 2021(m)31 Dec 2022: estimate (m); actual -2.0531 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.5431 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.7031 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.2131 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.21(m)(m)
1 Jan 202431 Dec 2024(m)-0.70(m)(m)
1 Jan 202331 Dec 2023(m)-0.54(m)(m)
1 Jan 202231 Dec 2022(m)-2.05(m)(m)
1 Jan 202131 Dec 2021(m)-2.36(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 2.27M ■ Earnings -69.36M — Profit margin -3052.60%

-82.27M-3053.6%-37.79M-2058.1%6.68M-1062.7%51.16M-67.2%31 Mar 2025: revenue 9.18M; earnings -46.88M; profit margin -510.93%31 Mar 202530 Jun 2025: revenue 8.70M; earnings -50.47M; profit margin -580.17%30 Jun 202531 Mar 2026: revenue 38.25M; earnings -26.09M; profit margin -68.21%31 Mar 202630 Jun 2026: revenue 2.27M; earnings -69.36M; profit margin -3052.60%30 Jun 2026

31 Dec 2025 ■ Revenue 42.73M ■ Earnings -204.38M — Profit margin -478.33%

-242.50M-4435.7%-111.19M-2973.7%20.12M-1511.7%151.43M-49.8%31 Dec 2022: revenue 3.65M; earnings -161.82M; profit margin -4434.72%31 Dec 202231 Dec 2023: revenue 113.31M; earnings -57.51M; profit margin -50.76%31 Dec 202331 Dec 2024: revenue 108.30M; earnings -97.01M; profit margin -89.57%31 Dec 202431 Dec 2025: revenue 42.73M; earnings -204.38M; profit margin -478.33%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$3.37(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$3.37High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning WVE

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-202.47M
Profit margin
-309.73%
Return on assets · 12 month
-49.95%
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
317.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
3.34M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-16.13%*
Total return · month
-27.63%*
Total return · quarter
-35.92%*
Total return · half year
-42.86%*
Total return · year to date
-78.59%*
Total return · 1 year
-48.95%*
Total return · 3 years
-36.70%*
Total return · 5 years
-25.56%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$65.37M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

WAVE LIFE SCIENCES LTD. Overview

View more →

(m)

(m)

SEC CIK
1631574
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
733 CONCORD AVENUE, CAMBRIDGE, Massachusetts, 02138, United States
Fiscal year end
1231
Phone
617-949-2900

Similar stocks

Stock NameCountryMarket CapPE Ratio
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
GERON CORP (GERN)United States$0.803B-12.14
Faeth Therapeutics, Inc. (FTH)United States$0.750B
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44